Literature DB >> 6122185

High affinity [3H]ethylketazocine binding: evidence for specific kappa receptors.

P L Wood, S Charleson.   

Abstract

A study has been made of the inactivation of mu(mu) ([3H]-dihydromorphine), delta (delta) ([3H](D-ala2-D-leu5)enkephalin) and kappa (kappa) ([3H]ethylketazocine) opiate receptor binding sites by N-ethylmaleimide (NEM) and it was observed that in contrast to mu and delta sites, the kappa sites of rat brain membrane preparations were resistant to low concentrations of N-ethylmaleimide. Furthermore, this kappa site was selectively protected, from inactivation with high concentrations of N-ethylmaleimide, by the kappa agonists ethylketazocine and (-)-alpha-(1R,5R,9R)-5,9-dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzo morphan (MR-2034) but not by morphine or (D-ala2-D-leu5)-enkephalin. These studies suggest that a unique kappa receptor is present in the rat CNS.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122185     DOI: 10.1016/0028-3908(82)90190-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  WIN 44,441: A Stereospecific and Long-Acting Narcotic Antagonist.

Authors:  P L Wood; C Pilapil; M Thakur; J W Richard
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

2.  Identification of benzomorphan-kappa opiate receptors in cerebral arteries which subserve relaxation.

Authors:  B T Altura; B M Altura; R Quirion
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

3.  Preparation of brain membranes containing a single type of opioid receptor highly selective for dynorphin.

Authors:  I F James; C Chavkin; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

4.  Visualization and solubilization of rat brain opiate receptors with a "kappa" ligand selectivity pattern.

Authors:  R Quirion; W D Bowen; M Herkenham; C B Pert
Journal:  Cell Mol Neurobiol       Date:  1982-12       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.